MMIL_en

13 Dec 2021 | Unclassified

MMIL A disease characterised by the multiplication of cancerous cells in the bone marrow, multiple myeloma affects around 4,000 new patients each year in France, for whom current treatments do not, in the majority of cases, provide a complete cure. The MMIL project...

CLUSTER_en

13 Dec 2021 | Unclassified

CLUSTER The accumulation of fluid in the serosa is an important event in the progression of adenocarcinoma. These malignant effusions are characterised by the presence of carcinoma cells. Their presence indicates disease progression and is associated with shorter...

DEMETEAR_en

13 Dec 2021 | Unclassified

DEMETEAR With an occurrence of approximately 2500 new cases per year in France, B-cell chronic lymphocytic leukaemia (CLL) is a major public health issue. The clinical management of patients, both in the first line and in relapse, has been revolutionised by the...

IMMUSPHINX_en

13 Dec 2021 | Unclassified

IMMUSPHINX: Targeting sphingolipid metabolism to improve the efficacy of immunotherapies in melanoma. Immune checkpoint inhibitors (ICIs) have shown an unprecedented and long-lasting anti-tumour response in patients with metastatic melanoma. To increase the proportion...

Pin It on Pinterest

Centre de Recherches en Cancérologie de Toulouse
Privacy Policy

To improve your browsing experience. Cookies provide information on how the site is used: statistics such as the number of visitors, the average length of visits or the number of pages viewed. On the other hand, disabling cookies may prevent you from using certain features, such as sharing content via social networks.
By clicking "Accept", you agree to the use of cookies from this site and to our privacy policy.

You can adjust all your cookie settings by navigating the tabs on the left.